GlassScriptPhysician profile
Jorge Diaz
NPI 1306817804
$16,102.13
in general payments reported to CMS, 2019-2025
44 companies · $2,386 in 2025
The $2,386 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,076 · 2020: $1,907 · 2021: $1,588 · 2022: $2,435 · 2023: $2,793 · 2024: $2,917 · 2025: $2,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,934 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,934.29 |
| Education | $161.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,569.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,035.10 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,876.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,446.19 | 2019-2025 | Jardiance, Tradjenta, Glyxambi |
| Amgen INC. | $941.58 | 2019-2025 | Prolia, Evenity, Otezla |
| Janssen Pharmaceuticals, INC | $818.69 | 2019-2024 | Xarelto |
| Pfizer INC. | $759.37 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $695.01 | 2019-2024 | Verquvo, Belsomra, Dificid |
| Glaxosmithkline, LLC. | $602.25 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $571.76 | 2022-2025 | |
| Astellas Pharma US INC | $478.23 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $294.21 | 2021-2025 | Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $284.51 | 2019-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $274.10 | 2019-2024 | |
| Radius Health, INC. | $253.84 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.